Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Poll results highlighted key lung cancer abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025 

Panelists discuss how insights from the Liso-cel combined with ibrutinib (ibr) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and small lymphocytic lymphoma (SLL) are highlighted through the primary results of the open-label, phase 1/2 Transcend CLL 004 study.

Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

Panelists discuss how the updated results from Arm 8 of the Epcore NHL-2 trial on Fixed-Duration Epcoritamab + R-Mini-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) ineligible for full-dose R-CHOP may influence treatment selection by offering a potentially effective alternative for this patient population

Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Ultra-low PSA responses were linked with prolonged rPFS and delayed times to mCRPC and PSA progression for patients with mHSPC treated with darolutamide.

Ultra-Low PSA Response With Darolutamide/ADT Correlates With Better Outcomes in mHSPC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

OncLive App

Interactive Tools

Biomarker Consortium

Subscribe

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

THE001, a doxorubicin-encapsulating thermosensitive liposome therapy, has been granted FDA orphan drug designation for soft tissue sarcoma.

THE001 Receives Orphan Drug Designation for Soft Tissue Sarcoma 

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

 team as an assistant editor in 2025 after previously working on the 

Belzutifan was safe and effective in patients with von Hippel-Lindau–associated RCC and other neoplasms.

Belzutifan Displays Robust Activity in VHL-Associated RCC

Amer Zeidan, MBBS, discusses evolutions in the myelodysplastic syndrome treatment paradigm and ongoing research seeking to improve treatment efficacy.  

Novel Agents and Personalized Biomarkers May Propel a New Era of MDS Management

The ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data. 

Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

CME Opportunities

Specialty

OncLive Peer Exchange®

Current and Emerging Therapies in NSCLC

Videos

Case Study: Treating an Elderly Patient With Squamous NSCLC

Case Study: Maintenance Therapy in Squamous NSCLC

Case Study: Mutation-Negative Patient With Adenocarcinoma

PRONOUNCE Trial: Two Drug Versus Three Drug Regimens

Case Study: Second-Line Treatment of Adenocarcinoma

Case Study: MET and ALK Targeted Therapies in NSCLC

Case Study: Progression on ALK Inhibitors in NSCLC

Case Study: Treating KRAS-Mutant Adenocarcinoma

Targeting the Immune System in Non-Small Cell Lung Cancer

Novel Immunotherapy Combinations in NSCLC

GALAXY-1 Trial: Investigation of Hsp90 Inhibition in NSCLC

Selecting a First-Line EGFR Inhibitor in NSCLC

Conclusion: Final Thoughts on Treatment Advances in NSCLC

Current and Emerging Therapies in NSCLC

Latest Conference Coverage